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Background: A subset of severe asthma patients has fixed airways obstruction, which is characterized by
incomplete reversibility to bronchodilator challenge. We aimed to elucidate the factors associated with fixed
airways obstruction in a cohort of patients with severe asthma in Singapore.
Methods: 245 patients from the Singapore General Hospital-Severe Asthma Phenotype Study (SGH-SAPS) were
screened. These patients fulfilled World Health Organization criteria for “treatment-resistant severe asthma” and
were all on combination of high-dose inhaled corticosteroids and long-acting beta2 agonists. 76 patients had
pre- and postbronchodilator lung function tests and were selected for analysis. They were divided into two
groups based on postbronchodilator (Post BD) forced expiratory volume in one second, PostBDFEV1 % predicted:
≥70% (Non-Fixed Obs) and < 70% (Fixed Obs). We compared clinical and demographic parameters between the
two groups.
Results: Patients in the Fixed Obs group were more frequently past or current smokers and had a higher pack-year
smoking history. Overall, pack-year smoking history had a modest negative correlation with PostBDFEV1 % predicted.
Atopy, allergen sensitization (type and numbers), comorbidities, symptoms, health care utilization and medication use
did not differ between the two groups. The prebronchodilator FEV1 % predicted, FEV1/FVC and FVC % predicted were
significantly lower in the Fixed Obs group. In addition, prebronchodilator FVC % predicted accounted for more variability
than FEV1/FVC in predicting PostBDFEV1% predicted.
Conclusion: Smoking is associated with fixed airways obstruction in patients with treatment-resistant severe asthma in
Singapore. Furthermore, our results suggest that both small and large airways obstruction contribute independently to
fixed airways obstruction in severe asthma.
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Asthma affects an estimated 315 million adults world-
wide [1] and incurs substantial health care and socioeco-
nomic costs [2]. Only 5% of all asthmatics have severe
asthma, but they disproportionately account for most of
the morbidity, mortality and health care burden across
all asthma patients [3].
Even among those with severe disease, asthma is hetero-
geneous and consists of multiple phenotypes [4]. The fixed
airways obstruction phenotype occurs in a small proportion* Correspondence: mariko.koh.s.y@sgh.com.sg
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unless otherwise stated.of patients who experience irreversible airways obstruction
despite inhaled corticosteroids or bronchodilators [5,6].
Fixed airways obstruction in asthma is associated with
more frequent exacerbations [7], increased asthma-related
mortality [8] and overall mortality [9]. The causes of fixed
obstruction in asthma are unknown but may be related to
the presence of airway wall remodeling, which is character-
ized by increased airway smooth muscle mass and airway
wall fibrosis [10].
Studies in American [11], European [12-15], Canadian
[16] and East Asian [17,18] cohorts have identified diverse
but sometimes conflicting risk factors for fixed airways
obstruction in asthma, including male sex, older age, longerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion, atopy and increased airway hyper-responsiveness.
These inconsistent results could reflect differences in study
methodologies, or the influence of gene-environment fac-
tors. We sought to elucidate the factors associated with
fixed airways obstruction in Singaporean patients with
severe asthma. To our knowledge, this is the first report to
characterize fixed airways obstruction among asthmatics in
a Southeast Asian cohort.Methods
Patient characteristics
We interrogated the Singapore General Hospital-Severe
Asthma Phenotype Study (SGH-SAPS) database, which
consisted of 245 patients with severe asthma who pre-
sented to the Allergy or Respiratory clinics at Singapore
General Hospital between 1 January 2011 and 31 December
2012. The diagnosis of asthma was made on the basis
of history of episodic wheeze and dyspnea, clinical exam-
ination and supported by spirometry where indicated (re-
versibility of forced expiratory volume in one second
(FEV1) of > 12% and 200 ml, or demonstration of bron-
chial hyper-responsiveness with a positive methacholine
challenge test, or FEV1 variability of > 15%). Diagnosis of
asthma was made by experienced clinicians in the field of
respiratory and allergy in our hospital. Severe asthma was
defined according to the World Health Organization clas-
sification of “treatment-resistant severe asthma” [19], that
is, patients who require a combination of high-dose in-
haled corticosteroids and long-acting beta agonists. Pa-
tients were considered to have treatment-resistant severe
asthma based on the above criteria and following a period
of treatment optimization, assessment of adherence, and
identification and treatment of other comorbidities. The
institution’s ethics committee approved the study and
waived the requirement for informed consent.Figure 1 Study participants.For the present analysis, we included 76 of the 245 pa-
tients (Figure 1) for whom postbronchodilator spirometry
data were available and divided them into two groups
based on postbronchodilator FEV1 % predicted: < 70%
(“Fixed Obs”, n = 44) and ≥ 70% (“Non-fixed Obs”, n = 32).
Design
This was a retrospective cross-sectional study.
Measurements and investigations
Asthma symptoms were evaluated using the Asthma Con-
trol Test [20]. We assessed for the presence of asthma-
related comorbidities of interest (allergic rhinitis, eczema,
reflux, obstructive sleep apnea, anxiety, depression, aspirin
sensitivity and vocal cord dysfunction) by obtaining history
and reviewing medical records. The number of admissions,
emergency visits, steroid bursts and medications over a
two year period (2011–2012) were determined by ques-
tioning patients and cross-checking the national network
of electronic health records, which contains discharge
summaries, investigation results, emergency department
records and electronic prescriptions from all public hospi-
tals in Singapore.
Patient medications were coded according to an ordinal
scale as follows: 1 = inhaled corticosteroid only, 2 = com-
bination inhaled corticosteroid and beta-agonist (Combi),
3 = Combi + theophylline, 4 = Combi + leukotriene recep-
tor antagonist (LTRA), 5 = Combi + Theophylline +
LTRA, 6 = Long term steroids, 7 =Omalizumab, 8 = Anti-
cholinergic, 9 = All of the above.
Spirometry was performed according to American
Thoracic Society/European Respiratory Society guide-
lines [21], using a Medgraphics, USA spirometer. Pre-
dicted values were obtained from Morris et al. [22] and
an adjustment factor of 0.94 was applied for FEV1 and
forced vital capacity (FVC) as recommended for Asian
patients [23]. Reversibility in FEV1 was measured 10 to
15 minutes after administration of 400 μg inhaled salbu-
tamol with a spacer, and was expressed as change in per-
centage predicted and absolute change in mls.
Skin prick tests were also retrospectively assessed and
were performed with a panel (Stallergenes, France) which
included the following extracts: dust mites (Bloomia tropi-
calis, Dermatophagoides pteronyssinus and farinae), dog
and cat danders, feathers, cockroach, and molds (Aspergil-
lus fumigatus), a negative control (glycerine) and positive
control (histamine, 10 mg/ml). A positive response was
defined as any wheal with a diameter 3 mm greater than
the negative control, 15 minutes after application.
Statistical analysis
Data were expressed either as mean ± standard deviation
(SD) for normally distributed continuous variables or al-
ternatively as median (interquartile range) for ordinal
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variables. Comparisons between groups were performed
using the Student’s t-test for normally distributed continu-
ous variables, the Mann–Whitney U test for ordinal and
for non-normally distributed continuous variables, or the
Chi-squared test for proportional data, as appropriate.
Correlations were investigated using either the Spearman
or Pearson tests. Hierarchical multiple linear regression
was used to assess the relationship between prebronchodi-
lator FEV1 and FEV1/FVC with PostBDFEV1. All variables
found to be significant correlated with postbronchodilator
FEV1 were evaluated for collinearity using a cut-off of tol-
erance < 0.2 or variable inflation factor > 5. Only predictor
variables found to be non-collinear were included in mul-
tiple linear regression analysis employing the Automatic
Linear Modelling module in SPSS version 20. Statistical
procedures were carried out with IBM SPSS version 20. P
values of less than 0.05 were considered significant.Results
Patient demographics
The characteristics of the SGH-SAPS cohort are reported
in Table 1. The distribution of ethnicity among the cohort
as compared to the general population in Singapore was
as follows: Chinese (66.5% vs. 76.8%), Malay (12.2% vs.
13.9%), Indian (15.1% vs. 7.9%), others (6.1% vs. 1.4%).
Overall, 44 patients (18%) out of our cohort of 245 severe
asthmatics had evidence of fixed airways obstruction, ac-
cording to the definition of postbronchodilator FEV1 <
70% predicted. Among the 76 patients with bronchodila-
tor testing, the mean age was 54.4 ± 18.2 years, the mean
age of onset was 35.5 ± 22.6 years. Age, age of onset,
duration of asthma, sex and body mass index were not
different between the Fixed Obs and Non-Fixed ObsTable 1 Baseline characteristics of the Singapore General Hos
Overall cohort S
Patients (n) 245 7
Age (years) 53.1 ± 19.0 5
Age of asthma onset (years) 32.2 ± 21.5 3
Duration of asthma (years) 20.9 ± 16.7 1






Current or past smokers (%) 21.6 2
Smoking history (pack-years) 0 (0–0) Range 0-64 0
Prebronchodilator FEV1 % (predicted) 72.2 ± 22.5 5
Data is presented as mean ± SD, proportion or median (interquartile range). FEV1 =groups (Table 2). The mean and 95% confidence inter-
val (CI) for age and age of onset for the Fixed Obs
group were 52.3 yrs ± 18.1 (95% CI: 46.8-57.8 yrs) and
32.8 ± 22.9 yrs (95% CI: 25.8-39.8 yrs), respectively.
Smoking
Table 2 and Figure 2 show the smoking history of subjects
according to PostBDFEV1 % predicted. The proportion of
current or past smokers was significantly higher for the
Fixed Obs group compared to the Non-Fixed Obs group
(p = 0.034). The former group also had a significantly
higher pack-year history than the latter (p = 0.022). In
addition, there was a significant negative correlation be-
tween pack-year smoking history and PostBDFEV1 % pre-
dicted (p = 0.004, rs = −0.306) with pack-year smoking
history accounting for approximately 9% of variability in
PostBDFEV1 % predicted (Figure 3).
Atopy, allergy tests and comorbidities
The prevalence of atopic diseases (allergic rhinitis, aspirin
sensitivity, eczema), allergen sensitization based on skin
prick tests, prevalence of other asthma-related comorbidi-
ties such as gastroesophageal reflux, obstructive sleep
apnea, vocal cord dysfunction, anxiety and depression
were not different between the Fixed Obs and Non-Fixed
Obs groups (Table 2).
Symptoms, psychological dysfunction, health care
utilization and medications
Symptom control as measured by the Asthma Control
Test was not different between groups. In addition, there
were no between-group differences in terms of emergency
visits, hospital admissions, near-fatal attacks, number of
short courses of oral steroids in the past year, and asthma
medication regimen.pital-Severe Asthma Phenotype Study cohort
tudy participants P-value (participants vs. non-participants)
6
4.4 ± 18.2 NS
5.5 ± 22.6 NS








(0–1) Range 0-64 NS
4.9 ± 17.2 <0.001
forced expiratory volume in one second, NS = not significant.
Table 2 Comparisons between subjects with fixed and non-fixed airways obstruction
Characteristic < 70% (“Fixed Obs) ≥ 70% (“Non-Fixed Obs”) p-value
Patients (n) 44 32
Age (years) 52.3 ± 18.1 57.4 ± 18.2 NS
Age of asthma onset (years) 32.8 ± 22.9 39.3 ± 21.9 NS
Before 12 years old (%) 34.1 18.8 NS
Before 18 years old (%) 36.4 18.8 NS
Before 40 years old (%) 50.0 50.0 NS
Duration of asthma (years) 19.5 ± 17.6 18.1 ± 13.5 NS
Gender (% Males) 56.8 40.6 NS
Body mass index (kg/m2) 25.2 ± 7.3 25.0 ± 5.5 NS
Serum eosinophils
No. of patients (n) 43 31
Absolute eosinophil count (× 109/L) 0.49 ± 0.73 0.46 ± 0.43 NS
Eosinophil count≥ 0.4 × 109/L (%) 37.2 51.6 NS
Smoking
Current or past smokers (%) 38.6 15.6 0.029
Smoking history (pack-years) 0 (0–10) 0 (0–0) 0.019
Range: 0-64 Range: 0-30
Comorbidities
Allergic Rhinitis (%) 45.5 53.1 NS
Eczema (%) 100 100 NS
Gastroesophageal reflux disease (%) 15.9 12.5 NS
Obstructive sleep apnea (%) 6.8 0 NS
Anxiety (%) 6.8 0 NS
Depression (%) 2.3 3.1 NS
Aspirin sensitivity (%) 0.0 3.1 NS
Vocal cord dysfunction (%) 2.3 0 NS
Skin prick tests
No. of patients (n) 14 14
Positive results on skin prick test to:
Blomia tropicalis (%) 78.6 92.9 NS
Dermatophagoides pteronyssinus (%) 85.7 85.7 NS
Dermatophagoides farinae (%) 85.7 85.7 NS
Dog (%) 64.3 50.0 NS
Cat (%) 50.0 50.0 NS
Feathers (%) 14.3 21.4 NS
Cockroach (%) 28.6 14.3 NS
Aspergillus (%) 14.3 7.1 NS
No. of allergens which test positive 5 (2.75-6) 4 (3–5.25) NS
Symptoms, health care use, medications
Asthma Control Test score 20 (16–22) 20 (19–24) NS
Admissions in the past 2 years 0 (0–0) (n = 42) 0 (0–2) (n = 31) NS
% admitted in past 2 years 14.3 32.3 NS
Emergency visits in the past 2 years 0 (0–2) (n = 43) 1 (0–2) (n = 31) NS
% with emergency visits in past 2 years 48.8 58.1 NS
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Table 2 Comparisons between subjects with fixed and non-fixed airways obstruction (Continued)
No. of steroid bursts in the past year 1 (0–2) 1 (0–2) NS
% with steroid bursts in the past year 61.4 71.9 NS
History of near-fatal asthma (%) 4.5 9.4 NS
Medication regimen 2 (2–4) 2 (2–4) NS
Lung function
PostBDFEV1 (% predicted)
Range 32-69 71-123 NA
Prebronchodilator FEV1 (% predicted) 45.1 ± 10.0 68.4 ± 15.9 <0.001
Prebronchodilator FVC (% predicted) 56.8 ± 16.8 74.6 ± 15.1 <0.001
Prebronchodilator FEV1/FVC (%) 61.3 ± 14.1 70.9 ± 12.0 0.003
Percentage reversibility in FEV1 (%) 26.8 ± 24.2 25.9 ± 18.6 NS
Reversibility in FEV1 (ml) 283 ± 222 360 ± 242 NS
Data is presented as mean ± SD, proportion or median (interquartile range).
FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, NS = not significant, NA = not applicable. Medication regimen is expressed as an
ordinal scale as follows: 1 = inhaled corticosteroid only, 2 = combination inhaled corticosteroid and beta-agonist (Combi), 3 = Combi + theophylline, 4 = Combi +
receptor antagonist (LTRA), 5 = Combi + Theophylline + LTRA, 6 = Long term steroids, 7 = Omalizumab, 8 = Anticholinergic, 9 = All of the above.
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The prebronchodilator FEV1 % predicted, FEV1/FVC and
FVC % predicted were significantly lower in the Fixed Obs
group compared to the Non-Fixed Obs group.
Correlational analysis
Bivariate analyses of the entire study sample (n = 76)
demonstrated that postbronchodilator FEV1 % predicted
was significantly correlated with the following continu-
ous or ordinal variables (Table 3): pack-year smoking
history, prebronchodilator FEV1, FVC, and FEV1/FVC,Figure 2 Pack-year smoking history of subjects according
to postbronchodilator FEV1 % predicted. Patients with
postbronchodilator FEV1 % < 70% had a higher pack-year
smoking than patients with postbronchodilator FEV1 % ≥ 70%
(Mann–Whitney, p = 0.022).and admissions in the past year. Collinearity diagnostics
revealed that among all the significantly correlated vari-
ables, prebronchodilator FEV1 had a high degree of multi-
collinearity (tolerance = 0.175, variable inflation factor =
5.717), hence it was removed from the final multiple linear
regression model. Multivariate regression incorporating all
other variables found to be significantly correlated with
postbronchodilator FEV1 % predicted (Table 4) showed
that the following variables were significantly and inde-
pendently associated with postbronchodilator FEV1, in
order of decreasing importance: prebronchodilator FVC %
predicted, prebronchodilator FEV1/FVC and smoking.Figure 3 The relationship between postbronchodilator forced
expiratory volume in one second % predicted versus pack-year
smoking history. Solid and dashed lines denote the fitted linear
regression curve and 95% confidence interval, respectively.
Table 3 Variables correlated with postbronchodilator forced expiratory volume in one second % predicted
Variable Correlation coefficient p-value
Age (years) 0.203# 0.08
Age of onset (years) 0.200# 0.09
Duration of asthma (years) −0.056# 0.63
Body mass index (kg/m2) 0.029# 0.80
Serum eosinophils (× 109/L) −0.092# 0.43
Pack-year smoking history −0.306* 0.007
Asthma control test score 0.143* 0.22
No. of emergency visits in past two years 0.102* 0.39
Steroid bursts in the past year 0.102* 0.38
Medication regimen 0.014* 0.90
Admissions in the past year 0.278* 0.015
Prebronchodilator FEV1 (% predicted) 0.882
# <0.001
Prebronchodilator FVC (% predicted) 0.650# <0.001
Prebronchodilator FEV1/FVC (%) 0.425
# <0.001
Reversibility (%) 0.012# 0.92
Reversibility (ml) 0.163# 0.16
Medication regimen is expressed as an ordinal scale as follows: 1 = inhaled corticosteroid only, 2 = combination inhaled corticosteroid and beta-agonist (Combi), 3 =
Combi + theophylline, 4 = Combi + leukotriene receptor antagonist (LTRA), 5 = Combi + Theophylline + LTRA, 6 = Long term steroids, 7 = Omalizumab, 8 = Anticholinergic,
9 = All of the above.
#Pearson coefficients, *Spearmann coefficients. FEV1 = forced expiratory volume in one second, FVC = forced vital capacity.
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FVC % predicted in predicting bronchodilator reversibility
Both prebronchodilator FEV1/FVC and FVC % pre-
dicted had a positive correlation with postbronchodila-
tor FEV1 % predicted (Figure 4). In order to discern the
relative importance of FEV1/FVC and FVC % predicted in
contributing to the variance of postbronchodilator FEV1, a
hierarchical multiple regression was performed. Entering
FEV1/FVC first led to a model with R
2 = 0.175, p < 0.001.
Subsequently, entering FVC % predicted into the model
led to a change in R2 of 0.508, p < 0.001, to a final R2 of
0.683. The combined model incorporating both FEV1/FVC
and FVC % predicted had standardized beta coefficients of
0.517 (p < 0.001) and 0.720 (p < 0.001) respectively.
Discussion
We aimed to elucidate the factors associated with fixed
airways obstruction in a cohort of patients with severe
asthma in Singapore. Smoking was found to be associatedTable 4 Multiple linear regression of factors correlated
with postbronchodilator FEV1 % predicted




Prebronchodilator (FEV1/FVC %) 0.606 <0.001 0.294
Pack-year smoking history −0.293 0.049 0.024
Admissions in the past year −4.921 NS 0.016with fixed airways obstruction. Pack-year smoking history
correlated modestly with the degree of fixed airways ob-
struction. There were also important differences in lung
function in asthma patients with fixed airways obstruction.
Those with fixed airways obstruction manifested with
lower prebronchodilator FEV1 % predicted, FVC % pre-
dicted and FEV1/FVC. FVC was found to account for
more variability than FEV1/FVC in predicting postbronch-
odilator FEV1 % predicted. These results suggest that both
small and large airways obstruction contribute independ-
ently to fixed airways obstruction in severe asthma.
Our findings are consistent with previous reports of an as-
sociation between smoking and fixed airways obstruction in
severe asthmatics (the TENOR [11] and COREA [17] stud-
ies), which reported prevalences of fixed airways obstruction
at 60% and 51% respectively. In both these studies, smoking
was a significant factor associated with fixed airways ob-
struction and both studies had relatively high smoking rates
among their patients (47% in TENOR and 56% in COREA).
In comparison, only 18% of our cohort of 245 patients had
fixed airways obstruction and our smoking rates (22%)
among the Fixed Obs and Non-Fixed Obs groups are lower
than the two studies, yet we found a significant association
between smoking and fixed airways obstruction. We were
also able to demonstrate this association despite our subjects
having a lower pack-year history when compared with the
COREA study. Bumbacea et al. [12] reported a group of pa-
tients with PostBDFEV1 < 50% predicted who had equivalent
pack-year history to our subjects with PostBDFEV1 < 70%
Figure 4 The relationship between prebronchodilator FEV1/FVC and FVC % predicted with postbronchodilator FEV1 % predicted. Solid
and dashed lines denote the fitted linear regression curve and 95% confidence interval, respectively.
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sociation of fixed obstruction with smoking. Notwithstand-
ing differences in study methodology, this discrepancy may
reflect gene-environment differences, where varying thresh-
olds of amount smoked lead to the development of fixed ob-
struction. Similarly, significant reductions in FVC have been
reported previously in asthmatics with severe irreversible
airflow obstruction [12]. However, to our knowledge, this is
the first study to report that FVC is a more important pre-
dictor than FEV1/FVC of the degree of fixed airways
obstruction.
There are several possible caveats in this study. First,
there was incomplete data on bronchodilator reversibil-
ity in our cohort. This partly reflects our institutional
practice of performing methacholine challenge, a test of
bronchial responsiveness, as an adjunct for diagnosing
asthma when patients have normal FEV1. Second, the
subjects with irreversible obstruction may have received
a misdiagnosis of asthma when in fact they have chronic
obstructive pulmonary disease (COPD). However, the
average age of onset of symptoms in subjects with Post-
BDFEV1 < 70% was 32.8 years (95% CI: 25.8-39.8 years),
whereas the onset of symptoms in COPD occurs mostly
after the age of 40 [24]. The average bronchodilator re-
versibility in the group with PostBDFEV1 < 70% was
26.8%, whereas reversibility in COPD in less marked (less
than 12-15%). Furthermore, asthma was diagnosed in our
patients after careful clinical evaluation by experienced cli-
nicians in the field of allergy and respiratory diseases. Pre-
vious work has shown that in patients with similar levels
of fixed obstruction, history can distinguish asthma and
COPD as separate airway pathologies [25,26]. Therefore, it
is unlikely that we have inadvertently included subjects
with COPD instead of asthma.
The third limitation is that the subjects in the present
study who have fixed airways obstruction may belong tothe asthma-COPD overlap syndrome. Overlap syndrome
is recognized by coexistence of increased variability of
airflow in a patient with incompletely reversible airways
obstruction [27]. Patients with overlap syndrome are
often excluded from clinical trials, and risk factors for the
development and natural history of overlap syndrome are
relatively unknown and unexplored. By definition, the dif-
ference between asthma with fixed obstruction and over-
lap syndrome is purely semantic and we are therefore
unable to exclude that our patients have overlap syn-
drome. Yet, the major implication of overlap syndrome is
that asthma and COPD are actually different manifesta-
tions of the same disease and share a common pathogenic
origin where one condition may evolve into the other,
referred to as the Dutch hypothesis [28]. The aim of the
present study was not to evaluate the Dutch hypothesis,
and our results do not support nor refute the Dutch
hypothesis.
The most likely inference is that the subjects with
PostBDFEV1 < 70% are asthma patients who have devel-
oped fixed obstruction in association with smoking. Our
results are also in keeping with longitudinal studies
showing accelerated lung function decline in asthma in-
dividuals who smoke compared to nonsmoking asth-
matics [29,30]. The reasons for this are several fold [31]:
smoking reduces corticosteroid sensitivity in asthmatics
[32,33]; exposure to cigarette smoke enhances not only
allergic Th2-driven inflammation [34], but also Th1-
mediated (neutrophilic) inflammatory responses [33]
which are not normally responsive to corticosteroids;
smoking causes impaired ciliary function [35] thus ren-
ders smokers more prone to upper and lower respiratory
tract infections i.e. more variability than frequent exacer-
bations [36].
Our results also shed light on the underlying patho-
physiological derangements associated with incomplete
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in asthma. FEV1 as a measure of obstruction may be
partitioned into components of air trapping (indicated
by FVC and reflecting small airways disease) and airflow
limitation (indicated by FEV1/FVC and reflecting large
airway luminal caliber) [37-40]. Asthma has traditionally
been attributed to large airway pathology [41], but we
found that FVC accounted for more variability than
FEV1/FVC in predicting postbronchodilator FEV1, sug-
gesting that small airways disease is at least as important
as large airways disease in contributing to fixed airways
obstruction. Our results resonate with an early study
[42] localizing the site of obstruction to the small air-
ways in asthmatics with fixed obstruction by analyzing
the variation in maximum expiratory flow volume curves
at different gas densities. More recently, air trapping as a
radiological finding has been reported as a significant
determinant of fixed obstruction in asthma [39,43]. Fur-
thermore, air trapping and small airways disease is a
unique feature of severe asthma that is absent in non-
severe asthma [44]. Preliminary studies show promising
results of therapies targeting distal airways, such as ul-
trafine bronchodilators and inhaled corticosteroids [45]
and leukotriene antagonists [46], but whether these
treatments can avert the development of fixed obstruc-
tion remains to be elucidated.
Our study also underscores the importance of smoking
cessation in asthma patients to mitigate the development
of irreversible airways obstruction. Several anti-smoking
strategies have been in place in Singapore since the 1970s,
including mandatory graphic health warnings on tobacco
products, prohibition of tobacco advertisements and pro-
motion, heavy tobacco taxation and a ban on smoking in
public places. Smoking prevalence in Singapore has de-
clined from 20% in 1984 to 12.6% in 2004, among the low-
est rates in the world. Despite this, we are confronted with
a fairly high prevalence of smoking in our cohort of severe
asthmatics (22%). This implies the need for intensified ef-
forts to promote smoking cessation in asthma patients in
order to harness the beneficial effects of smoking cessation
on asthma such as improvements in symptoms and lung
function [47].Conclusions
Smoking is associated with fixed airways obstruction in
patients with treatment-resistant severe asthma in
Singapore. Our findings underscore the importance of
smoking cessation in asthma patients to mitigate the
development of irreversible airways obstruction. In
addition, FVC % predicted was found to account for
more variability than FEV1/FVC in predicting post-
bronchodilator FEV1 % predicted. These results suggest
that both small and large airways disease contributeindependently to fixed airways obstruction in severe
asthma.
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